Krystal Biotech, Inc. (KRYS)
NASDAQ: KRYS · Real-Time Price · USD
253.69
-6.64 (-2.55%)
At close: Mar 6, 2026, 4:00 PM EST
251.00
-2.69 (-1.06%)
After-hours: Mar 6, 2026, 7:29 PM EST
Krystal Biotech Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Revenue | 389.13 | 290.52 | 50.7 | - | - | |
| Revenue Growth (YoY) | 33.95% | 473.02% | - | - | - | |
| Cost of Revenue | 23.05 | 20.06 | 3.09 | - | - | |
| Gross Profit | 366.08 | 270.45 | 47.61 | - | - | |
| Selling, General & Admin | 146.74 | 113.63 | 98.29 | 78.84 | 41.99 | |
| Research & Development | 58.05 | 53.58 | 46.43 | 42.46 | 27.88 | |
| Operating Expenses | 204.79 | 167.21 | 144.72 | 121.3 | 69.88 | |
| Operating Income | 161.3 | 103.25 | -97.12 | -121.3 | -69.88 | |
| Interest Expense | - | - | - | - | -1.49 | |
| Interest & Investment Income | 28.18 | 29.61 | 22.51 | 5.22 | 0.2 | |
| EBT Excluding Unusual Items | 189.47 | 132.86 | -74.6 | -116.08 | -71.17 | |
| Gain (Loss) on Sale of Assets | - | - | 100 | - | - | |
| Legal Settlements | - | -37.5 | -12.5 | -25 | - | |
| Pretax Income | 189.47 | 95.36 | 12.9 | -139.98 | -69.57 | |
| Income Tax Expense | -15.36 | 6.2 | 1.97 | - | - | |
| Net Income | 204.83 | 89.16 | 10.93 | -139.98 | -69.57 | |
| Net Income to Common | 204.83 | 89.16 | 10.93 | -139.98 | -69.57 | |
| Net Income Growth | 129.74% | 715.58% | - | - | - | |
| Shares Outstanding (Basic) | 29 | 29 | 27 | 25 | 22 | |
| Shares Outstanding (Diluted) | 30 | 30 | 28 | 25 | 22 | |
| Shares Change (YoY) | 0.71% | 7.16% | 8.87% | 14.85% | 18.15% | |
| EPS (Basic) | 7.08 | 3.12 | 0.40 | -5.49 | -3.13 | |
| EPS (Diluted) | 6.84 | 3.00 | 0.39 | -5.49 | -3.13 | |
| EPS Growth | 128.00% | 669.23% | - | - | - | |
| Free Cash Flow | 188.91 | 119.18 | -100.6 | -153.55 | -116.27 | |
| Free Cash Flow Per Share | 6.31 | 4.01 | -3.63 | -6.02 | -5.24 | |
| Gross Margin | 94.08% | 93.09% | 93.90% | - | - | |
| Operating Margin | 41.45% | 35.54% | -191.56% | - | - | |
| Profit Margin | 52.64% | 30.69% | 21.56% | - | - | |
| Free Cash Flow Margin | 48.55% | 41.02% | -198.43% | - | - | |
| EBITDA | 162.92 | 105.72 | -93.21 | -118.65 | -67.11 | |
| EBITDA Margin | 41.87% | 36.39% | -183.85% | - | - | |
| D&A For EBITDA | 1.62 | 2.47 | 3.91 | 2.64 | 2.77 | |
| EBIT | 161.3 | 103.25 | -97.12 | -121.3 | -69.88 | |
| EBIT Margin | 41.45% | 35.54% | -191.56% | - | - | |
| Effective Tax Rate | - | 6.50% | 15.24% | - | - | |
Source: S&P Capital IQ. Standard template.
Financial Sources.